

FORM AOC - 1

Pursuant to First Proviso to Sub-Section (3) of Section 129 of Companies Act, 2013 with the Rule 5 of Companies (Accounts) Rules, 2014
Statement Containing Salient Features of the Financial Statement of Subsidiaries / Associate Companies/ Joint Ventures

Sr No		Name of the subsidiary company	PART "A": Subsidiaries												₹ in Million	
		Date since when subsidiary was acquired	Reporting Currency	Rate	Capital	Reserve	Total Assets	Total Liabilities	Investment Other than Investment in Subsidiary	Turnover	Profit / (Loss) before Taxation	Provision for Taxation	Profit (Loss) after Taxation	Proposed Dividend	% of Shareholding	
1		Green Eco Development Centre Limited	12.11.2010	INR	1.00	7.0	(5.4)	1.6	0.0	-	-	(0.1)	-	(0.1)	-	100.00%
2		Sun Pharmaceutical (Bangladesh) Limited	29.03.2001	BDT	0.77	46.3	1,038.5	1,506.0	421.2	-	1,308.7	306.0	118.8	187.2	-	72.50%
3		Sun Pharmaceutical Industries, Inc.	14.06.2011	USD	64.93	13,872.9	2,382.6	81,682.8	65,427.3	7,297.4	35,759.0	(14,988.5)	(41.7)	(14,946.8)	-	100.00%
4		Sun Farmaceutica do Brasil Ltda.	22.05.2009	BRL	19.52	108.8	(2,397.6)	576.8	2,865.6	-	1,076.4	(168.5)	28.0	(196.5)	-	100.00%
5		Sun Pharma De Mexico S.A. DE C.V.	03.12.2002	MXN	3.52	3.6	669.8	988.9	315.5	-	1,267.0	263.0	88.3	174.7	-	75.00%
6		SPIIL De Mexico S.A. DE C.V.	13.02.2002	MXN	3.52	0.2	-	0.2	-	-	-	-	-	-	-	100.00%
7		Sun Pharmaceutical Peru S.A.C.	27.06.2006	PEN	20.11	0.0	(157.1)	0.2	157.3	-	(1.0)	-	(1.0)	-	-	99.33%
8		OOO "Sun Pharmaceutical Industries" Limited	12.11.2007	RUB	1.13	0.1	(169.1)	32.9	201.9	-	(1.3)	1.2	(2.5)	-	-	100.00%
9		Sun Pharma De Venezuela, C.A.	06.11.2011	VEF	0.01	0.1	(2.6)	0.8	3.3	-	-	3.6	-	3.6	-	100.00%
10		Chatterm Chemicals Inc.	24.11.2008	USD	64.93	2,235.8	1,023.4	3,426.4	167.2	-	1,436.5	(464.3)	(49.9)	(414.4)	-	100.00%
11		The Taro Development Corporation	20.09.2010	USD	64.93	0.0	(0.4)	1,289.2	1,289.6	-	-	-	-	-	-	100.00%
12		Alkaloida Chemical Company Zrt.	05.08.2005	USD	64.93	5,795.7	18,655.2	37,265.1	12,814.2	-	1,395.2	(99.5)	2.0	(101.5)	-	99.99%
13		Sun Pharmaceuticals UK Limited	20.06.2005	GBP	91.88	0.1	(0.1)	-	-	-	-	104.0	-	104.0	-	100.00%
14		Sun Pharmaceutical Industries (Australia) Pty Ltd	11.03.2008	AUD	49.78	3,467.0	(1,954.2)	8,532.6	7,019.8	-	3,501.1	(1,216.6)	-	(1,216.6)	-	100.00%
15		Aditya Acquisition Company Ltd.	22.04.2007	ILS	18.55	0.0	12.0	30.0	18.0	-	145.3	7.4	1.7	5.7	-	100.00%
16		Sun Pharmaceutical Industries (Europe) B.V.	29.06.2007	EURO	80.47	1.4	(67.5)	1,557.7	1,623.8	-	1,386.6	62.2	-	62.2	-	100.00%
17		Sun Pharmaceuticals Italia S.R.L.	14.04.2008	EURO	80.47	0.8	45.2	46.3	0.3	-	-	(0.9)	-	(0.9)	-	100.00%
18		Sun Pharmaceuticals Germany GmbH	11.08.2008	EURO	80.47	2.0	(209.2)	1,356.3	1,563.5	-	745.9	13.9	5.1	8.8	-	100.00%
19		Sun Pharmaceuticals France	10.02.2009	EURO	80.47	3.0	(27.7)	337.7	362.4	-	158.5	(4.8)	-	(4.8)	-	100.00%
20		Sun Pharma Global FZE	25.11.2008	USD	64.93	267.8	126,764.2	137,227.5	10,195.5	6,093.2	24,039.7	2,302.4	-	2,302.4	-	100.00%
21		Sun Pharmaceuticals (SA) (Pty) Ltd.	22.10.2008	ZAR	5.54	0.0	(0.1)	23.8	23.9	-	21.0	0.0	-	0.0	-	100.00%
22		Sun Global Canada Pty. Ltd.	23.06.2009	USD	64.93	0.1	(1.4)	-	1.3	-	-	(0.2)	-	(0.2)	-	100.00%
23		Sun Laboratories FZE	13.03.2011	USD	64.93	795.5	(1,060.6)	2,760.2	3,025.3	-	4,006.7	80.0	-	80.0	-	100.00%
24		Sun Global Development FZE	13.04.2011	USD	64.93	185.6	(4.8)	200.4	19.6	-	-	(0.7)	-	(0.7)	-	100.00%
25		Sun Pharma Japan Ltd.	01.03.2012	JPY	0.61	97.0	(1,574.8)	1,751.4	3,229.2	-	25.7	(1,008.6)	0.2	(1,008.8)	-	100.00%
26		Sun Pharma Philippines, Inc.	08.12.2011	PHP	1.24	10.7	(452.5)	232.6	674.4	-	296.8	(32.9)	27.7	(60.6)	-	100.00%
27		Sun Pharma Healthcare FZE	25.03.2012	USD	64.93	185.6	(2.2)	183.5	0.1	-	-	2.2	-	2.2	-	100.00%
28		Sun Pharmaceuticals Korea Ltd.	20.09.2011	KRW	0.06	6.1	(1.6)	6.1	1.6	-	-	0.0	-	0.0	-	100.00%
29		Caraco Pharmaceuticals Private Limited	12.01.2012	INR	1.00	0.1	(0.1)	0.0	0.0	-	-	(0.0)	-	(0.0)	-	100.00%
30		Sun Pharma Laboratories Ltd	09.03.2012	INR	1.00	0.5	196,823.2	227,734.3	30,910.6	5,714.3	51,099.1	11,582.4	2,820.2	8,762.2	4,790.0	100.00%
31		Morley & Company, Inc.	05.05.1983	USD	64.93	0.2	(0.1)	0.2	0.1	-	-	-	-	-	-	100.00%
32		Taro Pharmaceutical Industries Ltd. (TARO)	20.09.2010	USD	64.93	44.2	143,136.8	147,281.9	4,100.9	20,731.6	16,014.2	14,710.9	1,001.0	13,709.9	-	74.82%

₹ in Million

FORMAOC -1

Pursuant to First Proviso to Sub-Section (3) of Section 129 of Companies Act, 2013 with the Rule 5 of Companies (Accounts) Rules, 2014
Statement Containing Salient Features of the Financial Statement of Subsidiaries / Associate Companies/ Joint Ventures

Sr No		Name of the subsidiary company	Date since when subsidiary was acquired	Reporting Currency	Rate	Capital	Reserve	Total Assets	Total Liabilities	Investment Other than Investment in Subsidiary	Turnover	Profit / (Loss) before Taxation	Provision for Taxation	Profit / (Loss) after Taxation	Proposed Dividend	% of Shareholding	
		PART "A": Subsidiaries															₹ in Million
33	Taro Pharmaceuticals Inc.	20.09.2010	CAD	50.33	12,148.2	79,783.5	95,373.7	3,442.0	25,308.2	17,627.8	6,009.7	1,182.6	4,827.1	-	-	74.82%	
34	Taro Pharmaceuticals U.S.A., Inc.	20.09.2010	USD	64.93	9.4	(1,730.1)	31,562.4	33,283.1	-	34,905.9	662.8	2,889.6	(2,226.8)	-	-	74.82%	
35	Taro Pharmaceuticals North America, Inc.	20.09.2010	USD	64.93	0.0	32,776.4	32,776.4	-	4,310.8	-	12,035.2	-	12,035.2	-	-	74.82%	
36	Taro Pharmaceuticals Europe BV.	20.09.2010	EURO	80.47	1.4	2.6	44.2	40.2	-	-	40.6	-	40.6	-	-	74.82%	
37	Taro Pharmaceuticals Ireland Ltd	20.09.2010	EURO	80.47	40.3	(40.3)	-	-	-	-	(304.0)	-	(304.0)	-	-	74.82%	
38	Taro International Ltd.	20.09.2010	USD	64.93	0.0	578.5	1,094.1	515.6	-	1,698.4	203.7	49.1	154.6	-	-	74.82%	
39	Taro Pharmaceuticals (UK) Ltd.	20.09.2010	GBP	91.88	0.0	(0.0)	-	-	-	-	842.3	-	842.3	-	-	74.82%	
40	Taro Pharmaceuticals Canada, Ltd.	20.09.2010	CAD	50.33	0.0	0.1	0.1	-	-	-	0.1	-	0.1	-	-	74.82%	
41	Alkaloids Sweden AB	22.11.2012	SEK	7.83	55.8	(17.3)	143.0	104.5	-	696.0	17.0	-	17.0	-	-	100.00%	
42	Dusa Pharmaceuticals, Inc.	19.12.2012	USD	64.93	0.6	8,105.4	10,527.3	2,421.3	-	6,090.7	1,674.8	(1,360.9)	3,035.7	-	-	100.00%	
43	Mutual Pharmaceutical Company Inc.	05.02.2013	USD	64.93	0.0	9,127.2	9,211.3	84.1	-	4,380.5	1,611.0	1,676.4	(65.4)	-	-	100.00%	
44	Faststone Mercantile Company Private Limited	01.04.2012	INR	1.00	0.1	11.4	11.5	0.0	-	-	0.5	0.1	0.4	-	-	100.00%	
45	Neetnav Real Estate Private Limited	01.04.2012	INR	1.00	0.1	2,920.8	3,077.3	156.4	-	1.3	0.8	0.2	0.6	-	-	100.00%	
46	Realstone Multitrade Private Limited	01.04.2012	INR	1.00	0.1	11.4	11.6	0.1	-	-	0.5	0.1	0.4	-	-	100.00%	
47	Skisen Labs Private Limited	01.04.2012	INR	1.00	163.6	(163.6)	0.1	0.1	0.0	(0.0)	(0.0)	-	(0.0)	-	-	100.00%	
48	Softdeal Trading Company Private Limited	01.04.2012	INR	1.00	0.1	10.9	11.0	0.0	-	-	0.5	0.1	0.4	-	-	100.00%	
49	Universal Enterprises Private Limited	31.08.2012	INR	1.00	4.5	0.8	5.3	0.0	-	-	(0.0)	-	(0.0)	-	-	100.00%	
50	Sun Pharma Switzerland Ltd.	10.06.2013	CHF	68.26	6.8	(5.4)	14.0	12.6	-	-	(2.1)	-	(2.1)	-	-	100.00%	
51	Sun Pharma Holdings	06.08.2015	USD	64.93	222,115.3	(18,087.6)	204,784.9	757.2	-	-	(29.7)	-	(29.7)	-	-	100.00%	
52	Pharmalucence, Inc.	15.07.2014	USD	64.93	0.0	5,469.1	7,217.9	1,748.8	-	2,423.7	353.9	(69.7)	423.6	-	-	100.00%	
53	PI Real Estate Ventures LLC	15.07.2014	USD	64.93	584.5	321.9	1,993.0	1,086.6	-	214.3	135.1	28.4	106.7	-	-	100.00%	
54	Sun Pharma East Africa Limited	13.06.2014	KES	0.64	0.1	(105.6)	358.6	464.1	-	363.3	(75.8)	(22.4)	(53.4)	-	-	100.00%	
55	Basics GmbH	24.03.2015	EURO	80.47	392.3	372.6	5,320.2	4,555.3	-	3,164.3	89.5	35.3	54.2	-	-	100.00%	
56	Ranbaxy GmbH	24.03.2015	EURO	80.47	2.0	-	5.2	3.2	-	65.2	-	-	-	-	-	100.00%	
57	"Ranbaxy Pharmaceuticals Ukraine" LLC	24.03.2015	UAH	2.45	98.0	37.7	208.4	72.7	-	731.9	38.0	6.8	31.2	-	-	100.00%	
58	Sun Pharmaceuticals Morocco LLC (Formerly known as Ranbaxy Morocco LLC)	24.03.2015	MAD	7.09	86.8	(159.5)	1,236.2	1,308.9	-	1,224.6	48.0	53.8	(5.8)	-	-	100.00%	
59	Sun Pharmaceutical Industries S.A.C. (Formerly known as Ranbaxy - PRP Peru) S.A.C.)	24.03.2015	PEN	20.11	87.3	(211.8)	229.7	354.2	-	301.3	(29.8)	-	(29.8)	-	-	100.00%	
60	Ranbaxy Holdings (U.K.) Limited	24.03.2015	GBP	91.88	2,807.4	140.7	2,948.9	0.8	-	-	167.3	-	167.3	-	-	100.00%	
61	Ranbaxy Pharmacie Genériques	24.03.2015	EURO	80.47	2,007.6	(4,206.7)	986.5	3,185.6	-	1,501.9	(273.6)	-	(273.6)	-	-	100.00%	

FORM AOC - 1

Pursuant to First Proviso to Sub-Section (3) of Section 129 of Companies Act, 2013 with the Rule 5 of Companies (Accounts) Rules, 2014
Statement Containing Salient Features of the Financial Statement of Subsidiaries / Associate Companies/ Joint Ventures

Sr No		Name of the subsidiary company	PART "A": Subsidiaries											₹ in Million		
			Date since when subsidiary was acquired	Reporting Currency	Rate	Capital	Reserve	Total Assets	Total Liabilities	Investment Other than Investment in Subsidiary	Turnover	Profit / (Loss) before Taxation	Provision for Taxation	Profit / (Loss) after Taxation	Proposed Dividend	% of Shareholding
62 Office Pharmaceutique Industriel Et Hospitalier			24.03.2015	EURO	80.47	107.0	(13.2)	297.3	203.5	-	278.7	2.5	-	2.5	-	100.00%
63 Ranbaxy Italia S.P.A.			24.03.2015	EURO	80.47	4.0	0.1	2,222.8	2,218.7	-	1,734.7	(20.3)	1.6	(21.9)	-	100.00%
64 Ranbaxy Pharmaceuticals (Pty) Limited			24.03.2015	ZAR	5.54	1,108.4	(2,136.5)	6,406.5	7,434.6	-	6,836.0	195.2	-	195.2	-	100.00%
65 Sonke Pharmaceuticals Proprietary Limited			24.03.2015	ZAR	5.54	11.1	597.7	3,008.5	2,399.7	-	6,408.8	507.2	146.3	360.9	-	70.00%
66 Ranbaxy South Africa (Pty) Limited			24.03.2015	ZAR	5.54	97.0	688.0	2,544.6	1,759.6	-	1,617.1	1.9	(9.6)	11.5	-	100.00%
67 Sun Pharma Egypt Limited LLC (Formerly known as Ranbaxy Egypt Ltd)			24.03.2015	EGP	3.67	483.2	(96.0)	563.7	176.5	-	360.4	(14.1)	4.6	(18.7)	-	100.00%
68 Rexcel Egypt Company LLC			24.03.2015	EGP	3.67	0.9	(19.6)	5.6	24.3	-	(2.6)	(7.4)	-	(7.4)	-	100.00%
69 Ranbaxy (U.K.) Limited			24.03.2015	GBP	91.88	1,998.3	(614.5)	2,605.7	1,221.9	-	1,898.9	76.9	17.1	59.8	-	100.00%
70 Ranbaxy (Poland) SP. Z O.O.			24.03.2015	PLN	19.11	82.0	112.8	244.9	50.1	-	552.9	17.4	4.8	12.6	-	100.00%
71 Ranbaxy Nigeria Limited			24.03.2015	NGN	0.21	8.2	200.4	2,123.1	1,914.5	-	1,024.0	(428.7)	5.1	(433.8)	-	85.31%
72 Ranbaxy (Thailand) Co., Ltd.			24.03.2015	THB	2.08	238.8	(30.9)	990.0	782.1	-	1,290.3	30.9	-	30.9	-	100.00%
73 Ohm Laboratories, Inc.			24.03.2015	USD	64.93	15.5	7,124.6	214,538.0	207,397.9	-	15,381.5	2,810.9	(1,253.3)	4,064.2	-	100.00%
74 Ranbaxy Laboratories, Inc.			24.03.2015	USD	64.93	-	80.8	80.8	-	-	3,587.0	(568.7)	-	(568.7)	-	100.00%
75 Ranbaxy Signature LLC			24.03.2015	USD	64.93	3.2	354.8	497.7	139.7	-	528.7	411.6	-	411.6	-	67.50%
76 Ranbaxy Pharmaceuticals, Inc.			24.03.2015	USD	64.93	0.0	4.8	4.8	-	-	4,065.3	(3,117.3)	-	(3,117.3)	-	100.00%
77 Ranbaxy Inc.			24.03.2015	USD	64.93	-	642.3	750.8	108.5	-	-	(364.8)	(148.1)	(216.7)	-	100.00%
78 Ranbaxy Ireland Limited			24.03.2015	EURO	80.47	572.2	(2.0)	572.9	2.7	-	6.1	(8.1)	7.6	(15.7)	-	100.00%
79 AO Ranbaxy (Formerly Known ZAO Ranbaxy)			24.03.2015	RUB	1.13	183.8	835.4	4,038.9	3,019.7	-	5,999.8	147.2	75.6	71.6	-	100.00%
80 Laboratorios Ranbaxy, S.L.U.			24.03.2015	EURO	80.47	80.5	281.2	1,597.2	1,235.5	-	1,695.2	75.3	8.6	66.7	-	100.00%
81 Ranbaxy (Malaysia) SDN. BHD.			24.03.2015	MYR	16.80	139.4	740.8	1,641.3	761.1	-	2,006.2	495.6	-	495.6	-	90.74%
82 Ranbaxy Farmaceutica Ltda.			24.03.2015	BRL	19.52	339.0	(1,437.9)	1,060.0	2,158.9	-	1,716.4	(25.5)	48.2	(73.7)	-	100.00%
83 Ranbaxy Europe Limited			24.03.2015	GBP	91.88	0.0	-	0.0	-	-	-	(0.0)	-	(0.0)	-	100.00%
84 Sun Pharma ANZ Pty Ltd (Formerly known as Ranbaxy Australia Pty Ltd)			24.03.2015	AUD	49.78	866.2	(1,214.8)	973.8	1,322.4	-	2,163.3	83.1	-	83.1	-	100.00%
85 Ranbaxy Pharmaceuticals Canada Inc.			24.03.2015	CAD	50.33	113.3	164.9	877.8	599.6	-	1,181.0	(66.6)	-	(66.6)	-	100.00%
86 Terapia S.A.			24.03.2015	RON	17.27	432.1	14,702.3	17,868.5	2,734.1	-	11,851.9	2,643.3	350.7	2,292.6	-	96.81%
87 Be- Tabs Investments (Pty) Limited			24.03.2015	ZAR	5.54	0.0	19.8	19.8	-	-	-	(0.0)	-	(0.0)	-	100.00%
88 Sun Pharma (Netherlands) BV (Formerly known as Ranbaxy (Netherlands) B.V.)			24.03.2015	USD	64.93	44,039.3	8,655.3	53,355.2	660.6	923.6	0.0	(485.6)	95.5	(581.1)	-	100.00%
89 Insite Vision Incorporated			02.11.2015	USD	64.93	0.0	(349.9)	1,264.3	1,614.2	-	-	224.4	1,192.6	(968.2)	-	100.00%
90 JSC Biosintez			19.12.2016	RUB	1.13	0.3	723.1	4,700.1	3,976.7	2.3	2,906.1	80.7	72.5	8.2	-	85.10%

₹ in Million

FORMAOC - 1

Pursuant to First Proviso to Sub-Section (3) of Section 129 of Companies Act, 2013 with the Rule 5 of Companies (Accounts) Rules, 2014
Statement Containing Salient Features of the Financial Statement of Subsidiaries / Associate Companies/ Joint Ventures

Sr No	Name of the subsidiary company	Date since when subsidiary was acquired	Reporting Currency	Rate	Capital	Reserve	Total Assets	PART "A": Subsidiaries					Profit / (Loss) after Taxation	Proposed Dividend	% of Shareholding
								Total Liabilities	Investment Other than Investment in Subsidiary	Turnover	Profit / (Loss) before Taxation	Provision for Taxation			
91	Sun Pharmaceuticals Holdings USA, Inc	18.11.2016	USD	64.93	0.0	20,697.6	20,697.6	-	-	-	-	-	-	-	100.00%
92	Foundation for Disease Elimination and Control of India	21.09.2016	INR	1.00	0.1	3.9	4.8	0.8	-	42.8	5.1	-	5.1	-	100.00%
93	Zenotech Laboratories Ltd	27.07.2017	INR	1.00	610.3	(190.1)	817.4	397.2	-	111.4	(118.5)	-	(118.5)	-	57.56%
94	Sun Pharmaceutical Medicare Limited	16.01.2017	INR	1.00	2.5	(86.4)	3,077.1	3,161.0	-	1,199.2	(61.4)	-	(61.4)	-	100.00%

Note:

- 1 0.0' represents amount less than 0.05 Million and rounded off
- 2 In respect of entities at Sr. Nos. 4 to 8, 57, 79, 89 and 90 the reporting date is as of December 31, 2017 and different from the reporting date of the Parent Company. Adjustments have been made for significant transactions of these subsidiaries for the periods from January 01, 2017 to March 31, 2017 and January 01, 2018 to March 31, 2018, on the basis of their management accounts for the said periods.
- 3 Entities at Sr. No. 93 have been incorporated / acquired during the year ended March 31, 2018.
- 4 Foundation for Disease Elimination and Control of India (FDEC), a wholly owned subsidiary incorporated in India on September 21, 2016 by the Company as part of its Corporate Social Responsibility (CSR) initiative. FDEC has entered into an MOU with Indian Council of Medical Research (ICMR) and Madhya Pradesh State Government to undertake the Malaria Elimination Demonstration Project with a goal to eliminate Malaria in the state. FDEC is a Section 8 company not considered for consolidation since it can apply its income for charitable purposes only and can raise funds/contribution independently.
- 5 Taro Pharmaceutical India Private Limited has been liquidated on April 04, 2017.
- 6 With effect from December 21, 2017 S & I Ophthalmic LLC has been dissolved.
- 7 With effect from April 01, 2017 vide certificate dated August 09, 2017 Ocular Technologies SARL has been merged with Sun Pharma Switzerland Limited.
- 8 With effect from July 27, 2017 Zenotech Laboratories Limited has ceased to be an associate and has become subsidiary of Sun Pharmaceutical Industries Limited.
- 9 Books of accounts and other related records/documents of the overseas subsidiaries of the Zenotech Laboratories Limited were missing and due to non-availability of those records/information, Zenotech Laboratories Limited is unable to prepare consolidated accounts.
- 10 With effect from August 01, 2017, Ranbaxy Pharmaceuticals, Inc. and Ranbaxy Laboratories, Inc. has been merged with Sun Pharmaceutical Industries Inc.
- 11 With effect from May 20, 2018 Sun Pharmaceuticals UK Limited has been dissolved.
- 12 Taro Pharmaceuticals Ireland Limited is under Liquidation.
- 13 Taro Pharmaceuticals (UK) Limited is under Liquidation.
- 14 Ranbaxy Europe Limited is under Liquidation.
- 15 3 Skyline LLC and One Commerce drive LLC are being consolidated with Taro Pharmaceuticals U.S.A., Inc.
- 16 With effect from April 25, 2017 Insite Vision Ltd. has been dissolved.
- 17 With effect from June 19, 2017 MSD - Sun LLC is liquidated.
- 18 Fraizer Healthcare VII, L.P. and Versant Venture Capital V, L.P. were treated as associates till March 31, 2017 and are now being classified and measured as investments at fair value through profit or loss.
- 19 The above does not include Taro Pharmaceutical Laboratories Inc., 2 Independence Way LLC, URL PharmaPro LLC and Dungan Mutual Associates LLC as they have no operation and does not have any Assets, Liabilities or Equity as on the close of their Financial Year.

FORM AOC - 1

Pursuant to First Proviso to Sub-Section (3) of Section 129 of Companies Act, 2013 with the Rule 5 of Companies (Accounts) Rules, 2014

Statement Containing Salient Features of the Financial Statement of Subsidiaries / Associate Companies/ Joint Ventures

₹ in Million

Part "B": Associate Companies and Joint Ventures						
Sr. No	Name of Associates/Joint Ventures	Jointly Controlled Entity		Associates		
		Artes Biotechnology GmbH	S & I Ophthalmic LLC	sc Pharmaceuticals Inc.	Generic Solar Power LLP	Trumpcard Advisors and Finvest LLP
1	Latest audited Balance Sheet Date	31-Dec-17	31-Dec-17	31-Dec-17	31-Mar-18	31-Mar-18
	Date of acquisition	13.02.2014	28.10.2013	29.12.2016	09.10.2015	31.03.2017
2	Shares of Associate/Joint Ventures held by the company on the year end					
	No.	15,853	NA	13,000,000	28,760	NA
	Amount of Investment in Associates/ Joint Venture	252.8	-	867.6	0.0	444.6
	Extend of Holding %	45.00%	50.00%	11.69%	28.76%	40.61%
3	Description of how there is significant influence	NA	NA	NA	NA	NA
4	Reason why the associate/joint venture is not consolidated	NA	NA	NA	NA	NA
5	Networth attributable to Shareholding as per latest audited Balance Sheet	55.7	-	1,003.5	0.0	0.2
6	Profit / Loss for the year					
	i. Considered in Consolidation	7.6	(15.4)	(250.1)	(0.0)	132.1
	ii. Not Considered in Consolidation	9.3	(15.4)	(1,889.1)	0.0	193.2

For and on behalf of the Board of Directors of
Sun Pharmaceutical Industries Limited

DILIP S. SHANGHVI
Managing Director

SUDHIR V. VALIA
Wholtime Director

SAILESH T. DESAI
Wholtime Director
Mumbai, May 25, 2018

C. S. MURALIDHARAN
Chief Financial Officer

SUNIL R. AJMERA
Company Secretary